Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 1;278(2):172-178.
doi: 10.1097/SLA.0000000000005793. Epub 2023 Jan 3.

Long-Term Outcomes of Exercise Therapy Versus Revascularization in Patients With Intermittent Claudication

Takuro Shirasu  1   2 , Hisato Takagi  3 , Jun Yasuhara  4 , Toshiki Kuno  5 , K Craig Kent  1 , Behzad S Farivar  1 , Margaret C Tracci  1 , W Darrin Clouse  1
Affiliations

Long-Term Outcomes of Exercise Therapy Versus Revascularization in Patients With Intermittent Claudication

Takuro Shirasu et al. Ann Surg. .

Abstract

Objective: The aim was to analyze the risk of progression to chronic limb-threatening ischemia (CLTI), amputation and subsequent interventions after revascularization versus noninvasive therapy in patients with intermittent claudication (IC).

Background: Conflicting evidence exists regarding adverse limb outcomes after each treatment strategy.

Methods: Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. MEDLINE, Web of Science, and Google Scholar were searched aided by a health sciences librarian through August 16, 2022. Randomized control trials (RCTs) comparing invasive (endovascular or surgical revascularization) and noninvasive treatment (exercise and/or medical treatment) were included. PROSPERO registration was completed (CRD42022352831).

Results: A total of 9 RCTs comprising 1477 patients (invasive, 765 patients; noninvasive, 712 patients) were eligible. During a mean of 3.6-year follow-up, progression to CLTI after invasive [5 (2-8) per 1000 person-years] and noninvasive treatment [6 (3-10) per 1000 person-years] were not statistically different [rate ratio (RR): 0.77; 95% CI, 0.35-1.69; P =0.51, I2 =0%]. Incidence of amputation (RR: 1.69; 95% CI, 0.54-5.26; P =0.36, I2 =0%) and all-cause mortality (hazard ratio: 1.26; 95% CI, 0.91-1.74; P =0.16, I2 =0%) also did not differ between the groups. However, the invasive treatment group underwent significantly more revascularizations (RR: 4.15; 95% CI, 2.80-6.16; P <0.00001, I2 =83%). The results were not changed by fixed effect or random-effects models, nor by sensitivity analysis.

Conclusions: Although there is equivalent risk of progression to CLTI, major amputation and all-cause mortality compared with noninvasive treatment, invasive treatment for patients with IC led to significantly more revascularization procedures and should be used selectively in patients with major lifestyle limitation. Guideline recommendation of noninvasive treatment for first-line IC therapy is supported.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

References

    1. Fowkes FGR, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet Lond Engl. 2013;382:1329–1340.
    1. Kannel WB, Skinner JJ, Schwartz MJ, et al. Intermittent claudication. Incidence in the Framingham Study. Circulation. 1970;41:875–883.
    1. Dormandy J, Heeck L, Vig S. The natural history of claudication: risk to life and limb. Semin Vasc Surg. 1999;12:123–137.
    1. Kumakura H, Kanai H, Hojo Y, et al. Long-term survival and fate of the leg in de novo intermittent claudication. Eur Heart J Qual Care Clin Outcomes. 2017;3:208–215.
    1. Rantner B, Kollerits B, Pohlhammer J, et al. The fate of patients with intermittent claudication in the 21st century revisited—results from the CAVASIC Study. Sci Rep. 2017;8:45833.

Publication types

MeSH terms